Compare Raytheon Technologies Corp (RTX) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance

Raytheon Technologies CorpTrade

Vertex Pharmaceuticals IncorporatedTrade

Price performance (Past 24H)

Key statistics

Raytheon Technologies Corp vs Vertex Pharmaceuticals Incorporated — how do they compare? Raytheon Technologies Corp trades at $193.75 (market cap $261.85B), while Vertex Pharmaceuticals Incorporated trades at $481.09 (market cap $121.95B). The key difference: Raytheon Technologies Corp is far larger — about 2.1× Vertex Pharmaceuticals Incorporated's market cap, and Raytheon Technologies Corp pays a 1.5% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.

	RTX	VRTX
Market Cap	$261.85B	$121.95B
Sector	Industrials	Health
52-Week High	$212.16	$529.59
52-Week Low	$149.17	$366.54
Enterprise Value	$293.97B	$116.69B
Dividend Yield	1.5%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Raytheon Technologies Corp

RTX trades at $193.51, down 0.44% today, with a bullish technical signal and strong analyst support. Recent contract wins, including a $515 million Navy radar deal (PRNewsWire, June 3, 2026), and earnings beats in Q4 2025 and Q1 2026 highlight operational momentum. Revenue growth accelerated to $88.6 billion in 2025, with net income margin improving to 8.03%. The stock faces resistance near $196-$199, with support at $192.

The outlook remains positive given defense spending tailwinds and production expansions, but elevated P/E of 36.48 poses valuation risk. Analysts project 10% upside to a $213 consensus target, with no sell ratings. Key risks include debt levels and geopolitical volatility affecting contracts.

Vertex Pharmaceuticals Incorporated

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

RTX

OpenAI and Anthropic boost lobbying to $3.17M in Q2 ahead of IPOs and midtermsCNBC · 9 hours agoNeutral Collins Aerospace and Etihad Engineering form JV to expand aircraft MRO services in Abu Dhabi.PRNewsWire · 10 hours agoBullish Tigerair Taiwan orders 15 Airbus A321neos with fuel-efficient Pratt & Whitney GTF engines.PRNewsWire · 11 hours agoBullish View details →

VRTX

ARKG and GNOM ETFs offer different genomic bets with varied risk and returns in 2026.24/7 Wall Street · 12 hours agoNeutral View details →

About Raytheon Technologies Corp

Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.